<DOC>
	<DOCNO>NCT00313417</DOCNO>
	<brief_summary>Creatine new therapeutic strategy depression : A double-blind , parallel , randomize , add-on clinical trial creatine versus placebo add antidepressant treatment patient major depressive episode .</brief_summary>
	<brief_title>Creatine New Therapeutic Strategy Depression</brief_title>
	<detailed_description>Dr.Boris Nemetz Prof.Joseph Levine M.D. , Beer Sheva Mental Health Center , Israel . Creatine play pivotal role brain energy homeostasis , temporal spatial buffer cytosolic mitochondrial pool cellular energy currency adenosine triphosphate ( Wyss &amp; Kaddurah-Daouk , 2000 ) . Recent study suggest increased brain utilization oxygen follow oral creatine supplementation ( Persky &amp; Brazeua , 2001 ) . Creatine supplementation widely use enhance sport performance , try treatment neurological , neuromuscular atherosclerotic disease paucity side effect ( Persky &amp; Brazeua , 2001 ) . Creatine enters brain via specialized sodium dependent transporter . Dechent et al ( 1999 ) study effect oral creatine supplementation 20g/day 4 wk demonstrate significant increase mean concentration total creatine across brain region ( 8.7 % correspond 0.6mM , P &lt; 0.001 ) . Lyoo et al ( 2003 ) study magnetic resonance spectroscopy high-energy phosphate metabolite human brain follow oral supplementation creatine reporting creatine ( 0.3 g/kg/day first 7 day 0.03 g/kg/day next 7 day ) significantly increase brain creatine level . Accumulated evidence suggest possible involvement alter cerebral energy metabolism pathophysiology depression ( Mayberg , 1994 ) . Functional brain imaging study ( positron single photon emission tomography ) show decreased blood flow metabolism frontal lobes basal ganglion unipolar depression ( Kennedy et al , 2001 ; Derevets et al , 2002 ) . Proton magnetic resonance spectroscopy study study brain level creatine-containing compound . Kato et al ( 1992 ) report phosphocreatine significantly decrease severely ( oppose mildly ) depress patient . Dager et al ( 2004 ) study depressed mixed-state bipolar patient use two-dimensional proton echo-planar spectroscopic imaging , report inverse correlation severity depression white matter creatine level . Finally , several study suggest agent report antidepressant activity may increase brain level creatine contain compound . Sartorius et al ( 2003 ) use MRS study metabolic change hippocampus rat demonstrate significant creatine level rise induce electroconvulsive shock treatment occur specifically group animal exhibit depression-like [ learn helplessness ] behaviour ECT . S-adenosyl-L-methionine ( SAM ) acetyl-L-carnitine - report antidepressant effect - increase brain phosphocreatine level healthy subject ( Silveri et al , 2003 ) geriatric depressed patient ( Pettegrew et al , 2002 ) respectively . Taken together , finding suggest possibility use oral creatine supplementation increase brain level creatine contain compound therefore , likely modify high-energy phosphate metabolism hypoactive brain area , treat subject major depression . Open study creatine depression : A preliminary open study creatine monohydrate ( Roitman S , Green T , Osher Y , Karni N Joseph Levine , submit ) , suggest statistically significant beneficial effect creatine augmentation antidepressant treatment resistant major depression , possible precipitation manic switch resistant bipolar depression ( see table 1 result ) . Adverse reaction mild transitory include mild nausea flatus . Ww propose perform double-blind , parallel , randomize add-on clinical trial creatine versus placebo add current antidepressant treatment treatment major depressive disorder early phase treatment resistant major depressive episode . Early phase treatment resistant depressive episode define current treatment resistant depressive episode last 6 month . Based result open study present Tab.1 , hypothesize study show statistically significant clinically relevant difference active treatment ( creatine ) placebo double blind add-on trial design propose . Study design This study parallel , randomize , double blind , placebo control , 4 week clinical trial examine effect creatine versus placebo add antidepressant treatment subject major depression demonstrate lack adequate response current antidepressant treatment , administer adequate dose least 3 week . Creatine purchase Solgar LTD , Israel , 1 tablet contains 1 gram . Forty consent patient , woman men , 18 - 75 year old recruit . All subject primary diagnosis major depression , time recruitment experience major depressive episode duration ≥ 3 week &lt; 6 month . Subjects eligible enter study minimum score 18 point 24-item Hamilton Rating Scale Depression ( HAMD ) receive conventional antidepressant treatment adequate dose least 3 week mild improvement Blood cell count , liver kidney function perform enter study , patient perform last 6 month prior enter study . Pregnant lactating patient , clinically significant unstable medical condition , epilepsy , history alcohol substance abuse exclude study . All participant monitor weekly 24 hour telephone access researcher , develop suicidal aggressive behavior may endanger others , immediately discontinue study . The researcher evaluate HAM-D well study scale blind add-on treatment ( creatine placebo ) . Twenty patient treated creatine add-on 4 week ( 10 gram ) . The 20 patient receive placebo add-on 4 week . Patient 's antidepressant treatment change study participation . Benzodiazepines allow , dose exceed Lorazepam equivalent dose 4 mg daily . The following data record begin study : Demographic data Psychosocial data History hospitalization Comorbid medical condition Family history affective disorder Previous pharmacological treatment treatment response Seasonal pattern depressive symptomatology The following scale complete begin study weekly thereafter ( week 1 4 ) : Hamilton Depression Rating Scale ( 24 item ) Clinical Global Impression Backwards digit span test Scale assessment side effect The main outcome measure prediction sustain ≥ 50 % decrease Hamilton Depression Scale ( HAM-D ) total score versus baseline ( 'sustained response ' ) presence ≥20 % HAM-D total score improvement 1 week treatment ( 'early improvement ' ) presence ≥50 % HAM-D total score improvement 1 week treatment ( 'very early improvement ' ) . References Wyss M , Kaddurah- Daouk R. Creatine creatinine metabolism . Physiol Rev 2000 ; 80 : 1107-213 . Persky AM , Brazeau GA. Clinical pharmacology dietary supplement creatine monohydrate . Pharmac Rev 2001 ; 53 : 161-76 . Dechent P. , Pouwels PJ . Wilken B. et al . Increase total creatine human brain oral supplementation creatine-monohydrate . Am J Physiol 1999 ; 277 . R698-798 . Lyoo IK , Kong SW , Hirashima F. et al . Multinuclear magnetic resonance spectroscopy high-energy phosphate metabolite human brain follow oral supplementation creatine- monohydrate . Psychiatry Res 2003 ; 123:87-100 . Mayberg HS . Frontal lobe dysfunction secondary depression . J Neuropsychiatry Clin Neuroscience 1994 ; 6:428-442 . Kennedy SH , Evans KR , Kruger S , Mayberg HS , Meyer JH , McCann S , Arifuzzman AI , Houle S , Vaccarino FJ . Changes regional brain glucose metabolism measure positron emission tomography paroxetine treatment major depression . Am J Psychiatry 2001 Jun ; 158 ( 6 ) :899-905 . Drevets WC , Bogers W , Raichle ME . Functional anatomical correlate antidepressant drug treatment assess use PET measure regional glucose metabolism . Eur Neuropsychopharmacol 2002 Dec ; 12 ( 6 ) :527-44 . Kato T , Takahashi S , Shioiri T , Inubushi T : Brain phosphorous metabolism depressive disorder detect phosphorus-31 magnetic resonance spectroscopy . J Affect Disord 1992 ; 26 ( 4 ) :223-30 . Dager SR , Friedman SD , Parow A , Demopulos C , Stoll AL , Lyoo IK , Dunner DL , Renshaw PF : Brain metabolic alteration medication-free patient bipolar disorder . Arch Gen Psychiatry 2004 ; 61 ( 5 ) :450-8 . Sartorius A , Vollmayr B , Neumann-Haefelin C , Ende G , Hoehn M , Henn FA : Specific creatine rise learn helplessness induce electroconvulsive shock treatment . Neuroreport 2003 ; 14 ( 17 ) :2199-2200 . Silveri MM , Parow AM , Villafuerte RA , Damico KE , Goren J , Stoll AL , Cohen BM , Renshaw PF : S-adenosyl-L-methionine : effect brain bioenergetic status transverse relaxation time healthy subject . Biol Psychiatry 2003 ; 54 ( 8 ) :833-9 . Pettegrew JW , Levine J , Gershon S , Stanley JA , Servan-Schreiber D , Panchalingam K , McClure RJ : 31P-MRS study acetyl-L-carnitine treatment geriatric depression : preliminary result . Bipolar Disord 2002 ; 4 ( 1 ) :61-6 .</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<criteria>Age:1875</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Creatine</keyword>
	<keyword>major depressive disorder</keyword>
</DOC>